151 related articles for article (PubMed ID: 36807750)
21. Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma.
Ohmoto A; Sato Y; Asaka R; Fukuda N; Wang X; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Tomomatsu J; Toshiyasu T; Mitani H; Takeuchi K; Mori S; Takahashi S
Mod Pathol; 2021 Nov; 34(11):1979-1989. PubMed ID: 34247193
[TBL] [Abstract][Full Text] [Related]
22. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
[TBL] [Abstract][Full Text] [Related]
23. A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations.
Kobayashi H; Kosaka T; Nakamura K; Shojo K; Hongo H; Mikami S; Nishihara H; Oya M
BMC Med Genomics; 2021 Oct; 14(1):245. PubMed ID: 34627261
[TBL] [Abstract][Full Text] [Related]
24. Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix.
Bellone S; Jeong K; Halle MK; Krakstad C; McNamara B; Greenman M; Mutlu L; Demirkiran C; Hartwich TMP; Yang-Hartwich Y; Zipponi M; Buza N; Hui P; Raspagliesi F; Lopez S; Paolini B; Milione M; Perrone E; Scambia G; Altwerger G; Ravaggi A; Bignotti E; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Schwartz PE; Quick CM; Angioli R; Terranova C; Zaidi S; Nandi S; Alexandrov LB; Siegel ER; Choi J; Schlessinger J; Santin AD
Proc Natl Acad Sci U S A; 2024 Apr; 121(17):e2321898121. PubMed ID: 38625939
[TBL] [Abstract][Full Text] [Related]
25. PD-L1, RB1 and mismatch repair protein immunohistochemical expression in neuroendocrine carcinoma, small cell type, of the uterine cervix.
Morgan S; Slodkowska E; Parra-Herran C; Mirkovic J
Histopathology; 2019 Jun; 74(7):997-1004. PubMed ID: 30667073
[TBL] [Abstract][Full Text] [Related]
26. Muscle-invasive Urothelial Cancer: Association of Mutational Status with Metastatic Pattern and Survival.
Alessandrino F; Williams K; Nassar AH; Gujrathi R; Silverman SG; Sonpavde G; Shinagare AB
Radiology; 2020 Jun; 295(3):572-580. PubMed ID: 32228295
[TBL] [Abstract][Full Text] [Related]
27. Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder.
Liu F; Li Y; Ying D; Qiu S; He Y; Li M; Liu Y; Zhang Y; Zhu Q; Hu Y; Liu L; Li G; Pan W; Jin W; Mu J; Cao Y; Liu Y
Signal Transduct Target Ther; 2021 Feb; 6(1):55. PubMed ID: 33563892
[TBL] [Abstract][Full Text] [Related]
28. RB1 gene mutations are a distinct predictive factor in Merkel cell carcinoma.
Muto Y; Ryo E; Namikawa K; Takahashi A; Ogata D; Fujimura T; Yatabe Y; Aiba S; Yamazaki N; Mori T
Pathol Int; 2021 May; 71(5):337-347. PubMed ID: 33751708
[TBL] [Abstract][Full Text] [Related]
29. Next generation sequencing of Cytokeratin 20-negative Merkel cell carcinoma reveals ultraviolet-signature mutations and recurrent TP53 and RB1 inactivation.
Harms PW; Collie AM; Hovelson DH; Cani AK; Verhaegen ME; Patel RM; Fullen DR; Omata K; Dlugosz AA; Tomlins SA; Billings SD
Mod Pathol; 2016 Mar; 29(3):240-8. PubMed ID: 26743471
[TBL] [Abstract][Full Text] [Related]
30. Updates and management algorithm for neuroendocrine tumors of the uterine cervix.
Salvo G; Gonzalez Martin A; Gonzales NR; Frumovitz M
Int J Gynecol Cancer; 2019 Jul; 29(6):986-995. PubMed ID: 31263021
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive analysis of mutational and clinicopathologic characteristics of poorly differentiated colorectal neuroendocrine carcinomas.
Lee SM; Sung CO
Sci Rep; 2021 Mar; 11(1):6203. PubMed ID: 33737597
[TBL] [Abstract][Full Text] [Related]
32. Mutational analysis of PDGFRA oncogene in high-grade neuroendocrine carcinoma of the uterine cervix in twelve Taiwanese women.
Chang KL; Chao WR; Lee YJ; Lin YH; Han CP
Taiwan J Obstet Gynecol; 2024 Jan; 63(1):125-126. PubMed ID: 38216252
[No Abstract] [Full Text] [Related]
33. Multimodality therapy in early-stage neuroendocrine carcinoma of the uterine cervix.
Boruta DM; Schorge JO; Duska LA; Crum CP; Castrillon DH; Sheets EE
Gynecol Oncol; 2001 Apr; 81(1):82-7. PubMed ID: 11277655
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological characteristics and survival outcomes of patients with large cell neuroendocrine carcinoma of the uterine cervix: A systematic review and meta-analysis.
Prodromidou A; Phelps DL; Pergialiotis V; Cunnea P; Thomakos N; Rodolakis A; Fotopoulou C; Haidopoulos D
Eur J Obstet Gynecol Reprod Biol; 2022 Mar; 270():212-220. PubMed ID: 35093830
[TBL] [Abstract][Full Text] [Related]
35. The clinicopathological features and treatment modalities associated with survival of neuroendocrine cervical carcinoma in a Chinese population.
Zhang X; Lv Z; Lou H
BMC Cancer; 2019 Jan; 19(1):22. PubMed ID: 30616631
[TBL] [Abstract][Full Text] [Related]
36. Comparative Analysis of Genetic Alterations, HPV-Status, and PD-L1 Expression in Neuroendocrine Carcinomas of the Cervix.
Takayanagi D; Hirose S; Kuno I; Asami Y; Murakami N; Matsuda M; Shimada Y; Sunami K; Komatsu M; Hamamoto R; Kato MK; Matsumoto K; Kohno T; Kato T; Shiraishi K; Yoshida H
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33802174
[TBL] [Abstract][Full Text] [Related]
37. Polymorphic variability in the exon 19 of the RB1 gene and its flanking intronic sequences in HPV16-associated precancerous lesions in the Greek population.
Tsakogiannis D; Moschonas GD; Daskou M; Stylianidou Z; Kyriakopoulou Z; Kottaridi C; Dimitriou TG; Gartzonika C; Markoulatos P
J Med Microbiol; 2018 Nov; 67(11):1638-1644. PubMed ID: 30303478
[TBL] [Abstract][Full Text] [Related]
38. Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures.
Brcic L; Kuchler C; Eidenhammer S; Pabst D; Quehenberger F; Gazdar AF; Popper H
Diagn Pathol; 2019 May; 14(1):47. PubMed ID: 31109352
[TBL] [Abstract][Full Text] [Related]
39. [Clinical analysis of 32 cases with neuroendocrine carcinoma of the uterine cervix in early-stage disease].
Wang Z; Wu L; Yao H; Sun Y; Li X; Li B; Zhang R; Ma S; Huang M
Zhonghua Fu Chan Ke Za Zhi; 2015 Mar; 50(3):198-203. PubMed ID: 26268410
[TBL] [Abstract][Full Text] [Related]
40. Pancreatic neuroendocrine carcinoma G3 may be heterogeneous and could be classified into two distinct groups.
Tanaka H; Hijioka S; Hosoda W; Ueno M; Kobayashi N; Ikeda M; Ito T; Kodama Y; Morizane C; Notohara K; Taguchi H; Kitano M; Komoto I; Tsuji A; Hashigo S; Kanno A; Miyabe K; Takagi T; Ishii H; Kojima Y; Yoshitomi H; Yanagimoto H; Furuse J; Mizuno N
Pancreatology; 2020 Oct; 20(7):1421-1427. PubMed ID: 32891532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
